Cardiac troponin market is anticipated to grow at a significant CAGR during the forecast period. Cardiac troponins are known as cardiac biomarkers, also known as diagnostic markers, that are used as indicators of myocardial infarction. Cardiac troponin is found in skeletal muscles, and cardiac muscles of humans and increased levels of cardiac troponin circulating in the blood represents the onset of myocardial infarction. The market growth is majorly attributed owing to the growing prevalence of acute coronary syndrome, the rising number of cases of myocardial infarction, and thus, the need to diagnose CVD. As per the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of mortalities globally. An estimated 17.9 million people died from CVDs in 2019, representing 32% of all the mortalities globally. Further, out of the 17 million premature mortalities (under the age of 70) due to noncommunicable diseases in 2019, 38% were caused by CVDs.
Further, as per the American Heart Association (AHA), in the US, the total cost of heart-associated health expenditure is valued at more than $100 billion on an average, of which 70% is due to hospitalization. These stats call out for a novel approach that fosters the diagnosis of CVDs and thus, the reduction in the burden of healthcare costs due to faster and acute diagnosis. This factor is further anticipated to provide a boost to the overall market growth.
Some key players operating in the market include F. Hoffmann La-Roche AG, Abbott Laboratories, and Siemens Healthcare GmbH, among others. These players are fousing on strengthening their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on. For instance, in June 2018, Beckman Coulter Diagnostics received Health Canada clearance for its new high sensitivity troponin (hsTnI) assay, Access hsTnI, that aids in diagnosing myocardial infarction for patients presenting with chest pain or other ischemic symptoms.
To Request a Sample of our Report on Cardiac Troponin Market: https://www.omrglobal.com/request-sample/cardiac-troponin-market
Market Coverage
- The market number available for – 2021-2029
- Base year- 2021
- Forecast period- 2023-2029
Segment Covered-
- By Type
- By Application
Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape: F. Hoffmann La-Roche AG, Abbott Laboratories, and Siemens Healthcare GmbH, among others.
Cardiac Troponin Market Report by Segment
By Type
- Troponin I
- Troponin T
- Others
By Application
- Acute Coronary Syndrome
- Myocardial Infarction
- Congestive Heart Failure
- Others
A full Report of Cardiac Troponin Market is Available @ https://www.omrglobal.com/industry-reports/cardiac-troponin-market
Cardiac Troponin Market by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East and Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/cardiac-troponin-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
